-
公开(公告)号：US11564974B2
公开(公告)日：2023-01-31
申请号：US16338185
申请日：2017-09-28
IPC分类号： A61K38/22 , A61P19/08 , A61K38/27 , A61K31/505 , A61K45/06
摘要： The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that benefits from stimulating growth.
-
公开(公告)号：US20220331438A1
公开(公告)日：2022-10-20
申请号：US17842436
申请日：2022-06-16
摘要： The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
-
公开(公告)号：US20190255183A1
公开(公告)日：2019-08-22
申请号：US16269097
申请日：2019-02-06
发明人： Kennett Sprogøe , Ulrich Hersel , Harald Rau , Thomas Wegge , Frank Faltinger , Felix Cleemann , Nora Kaluza , Ana Bernhard , Annette Buba , Tom Woods
摘要： The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
-
公开(公告)号：US20230116746A1
公开(公告)日：2023-04-13
申请号：US17848180
申请日：2022-06-23
发明人： Kennett Sprogøe , Ulrich Hersel , Harald Rau , Thomas Wegge , Frank Faltinger , Felix Cleemann , Nora Kaluza , Ana Bernhard , Annette Buba , Tom Woods
摘要： The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
-
公开(公告)号：US20220296682A1
公开(公告)日：2022-09-22
申请号：US17526481
申请日：2021-11-15
摘要： The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
-
公开(公告)号：US11311604B2
公开(公告)日：2022-04-26
申请号：US16066980
申请日：2017-01-05
发明人： Harald Rau , Ulrich Hersel , Kennett Sprogøe , Frank Faltinger , Thomas Wegge , Felix Cleemann
摘要： The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.
-
公开(公告)号：US11224661B2
公开(公告)日：2022-01-18
申请号：US16067111
申请日：2017-01-05
发明人： Kennett Sprogøe , Harald Rau , Ana Bernhard , Ulrich Hersel , Felix Cleenmann , Thomas Wegge
摘要： The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
-
公开(公告)号：US20210077584A1
公开(公告)日：2021-03-18
申请号：US17005272
申请日：2020-08-27
摘要： The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
-
公开(公告)号：US11413351B2
公开(公告)日：2022-08-16
申请号：US16067095
申请日：2017-01-05
摘要： The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
-
公开(公告)号：US20210069339A1
公开(公告)日：2021-03-11
申请号：US16993127
申请日：2020-08-13
发明人： Kennett Sprogøe , Ulrich Hersel , Harald Rau , Thomas Wegge , Frank Faltinger , Felix Cleemann , Nora Kaluza , Ana Bernhard , Annette Buba , Tom Woods
摘要： The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.018 秒)
